Kreinin Anatoly, Lisson Serah, Nesher Elimelech, Schneider Jenny, Bergman Josef, Farhat Kamal, Farah Joseph, Lejbkowicz Flavio, Yadid Gal, Raskin Leon, Koman Igor, Pinhasov Albert
Maale HaCarmel Mental Health Center, Tirat HaCarmel, affiliated to Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Department of Molecular Biology, Ariel University, Ariel, Israel; Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
PLoS One. 2015 May 26;10(5):e0127643. doi: 10.1371/journal.pone.0127643. eCollection 2015.
Though the role of brain derived neurotrophic factor (BDNF) as a marker for major depressive disorder (MDD) and antidepressant efficacy has been widely studied, the role of BDNF in distinct groups of patients remains unclear. We evaluated the diagnostic value of BDNF as a marker of disease severity measured by HAM-D scores and antidepressants efficacy among MDD patients. Fifty-one patients who met DSM-IV criteria for MDD and were prescribed antidepressants and 38 controls participated in this study. BDNF in serum was measured at baseline, 1st, 2nd and 8th treatment weeks. Depression severity was evaluated using the Hamilton Rating Scale for Depression (HAM-D). BDNF polymorphism rs6265 (val66met) was genotyped. We found a positive correlation between blood BDNF levels and severity of depression only among untreated women with severe MDD (HAM-D>24). Serum BDNF levels were lower in untreated MDD patients compared to control group. Antidepressants increased serum BDNF levels and reduced between-group differences after two weeks of treatment. No correlations were observed between BDNF polymorphism, depression severity, duration of illness, age and BDNF serum levels. Further supporting the role of BDNF in the pathology and treatment of MDD, we suggest that it should not be used as a universal biomarker for diagnosis of MDD in the general population. However, it has diagnostic value for the assessment of disease progression and treatment efficacy in individual patients.
尽管脑源性神经营养因子（BDNF）作为重度抑郁症（MDD）的标志物及抗抑郁疗效的作用已得到广泛研究，但BDNF在不同患者群体中的作用仍不清楚。我们评估了BDNF作为通过汉密尔顿抑郁量表（HAM-D）评分衡量的疾病严重程度标志物以及MDD患者抗抑郁疗效的诊断价值。51名符合DSM-IV标准的MDD患者且正在服用抗抑郁药物，以及38名对照者参与了本研究。在基线、治疗第1周、第2周和第8周测量血清中的BDNF。使用汉密尔顿抑郁评定量表（HAM-D）评估抑郁严重程度。对BDNF基因多态性rs6265（val66met）进行基因分型。我们发现仅在未治疗的重度MDD（HAM-D>24）女性患者中，血液BDNF水平与抑郁严重程度呈正相关。未治疗的MDD患者血清BDNF水平低于对照组。抗抑郁药物治疗两周后可提高血清BDNF水平并缩小组间差异。未观察到BDNF基因多态性、抑郁严重程度、病程、年龄与BDNF血清水平之间存在相关性。进一步支持BDNF在MDD病理和治疗中的作用，我们建议它不应作为普通人群中MDD诊断的通用生物标志物。然而，它对个体患者疾病进展和治疗疗效的评估具有诊断价值。
